Neumora Therapeutics, Inc. (NMRA) - 10-Q Summary
Business Context and Reporting Period
Company: Neumora Therapeutics, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: June 30, 2026
Business Overview: Neumora is a clinical-stage biopharmaceutical company focused on developing novel therapies for brain and centrally mediated diseases using a precision neuroscience approach. The company has no approved products and has not generated revenue from product sales.
Key Pipeline Update: Following results from the Phase 3 KOASTAL program in June 2026, the Company discontinued development of navacaprant for major depressive disorder (MDD). The company is advancing NMRA-511 (Alzheimer's agitation), NMRA-898 (schizophrenia), and NMRA-215 (obesity/cardiovascular risk).
Key Financial Metrics
| Metric (in thousands) | Three Months Ended June 30, 2026 |
Three Months Ended June 30, 2025 |
Six Months Ended June 30, 2026 |
Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Loss | $(43,082) | $(52,731) | $(96,540) | $(120,723) |
| Net Loss Per Share (Basic/Diluted) | $(0.23) | $(0.33) | $(0.53) | $(0.75) |
| Operating Expenses | $42,190 | $54,040 | $95,054 | $124,976 |
| Research & Development (R&D) | $29,283 | $38,724 | $67,881 | $90,875 |
| General & Administrative (G&A) | $12,907 | $15,316 | $27,173 | $34,101 |
| Cash and Cash Equivalents (Balance Sheet) | $116,834 (as of June 30, 2026) | |||
| Long-Term Debt (Net) | $52,912 (as of June 30, 2026) | |||
| Accumulated Deficit | $(1,280,689) (as of June 30, 2026) |
Material Changes vs. Prior Period
- Expense Reduction: Total operating expenses decreased by $11.9 million (22%) for the three months ended June 30, 2026, compared to the same period in 2025. This was driven primarily by a $9.4 million decrease in R&D expenses and a $2.4 million decrease in G&A expenses.
- R&D Drivers: The reduction in R&D costs was largely due to the conclusion of the Phase 3 trial for navacaprant (MDD), resulting in an $8.9 million decrease in program costs for the quarter. NMRA-511 costs also decreased by $1.2 million following the completion of its Phase 1b study in 2025.
- Interest Expense: Interest expense increased significantly to $1.8 million for the quarter (from $0.4 million in 2025) due to higher term loan balances and associated costs.
- Cash Position: Cash and cash equivalents decreased from $182.5 million at December 31, 2025, to $116.8 million at June 30, 2026, reflecting a net cash outflow of $65.7 million for the six-month period.
Guidance, Outlook, Risks, and Contingencies
- Going Concern: The Company has concluded that substantial doubt exists about its ability to continue as a going concern within one year of the filing date. Current cash of $116.8 million is insufficient to fund operating plans for the next 12 months. The Company expects to finance future needs through equity or debt financings, collaborations, or other capital sources.
- Debt Obligations: The Company has a term loan facility with K2 HealthVentures LLC. As of June 30, 2026, $60.0 million in gross proceeds had been drawn. The interest-only period was extended to April 2029, with principal and fees due at maturity on May 1, 2029. A minimum liquidity covenant became effective July 1, 2026.
- Legal Proceedings: A putative securities class action lawsuit was filed in February 2025 regarding the Company's IPO, alleging false statements about navacaprant. The Company has moved to dismiss the complaint, and the case remains pending.
- Contingent Consideration: The Company has significant potential future obligations related to acquisitions (BlackThorn, Vanderbilt, Amgen) totaling hundreds of millions of dollars in development, regulatory, and sales milestones, payable in cash or stock.
Investor Verification Checklist
- Liquidity Runway: Verify the timeline and terms of any new financing arrangements required to address the "substantial doubt" regarding going concern status.
- Debt Covenants: Confirm compliance with the new minimum liquidity covenant effective July 1, 2026, and the impact of the variable interest rate (Prime + 2.95% or 10.45%).
- Pipeline Focus: Assess the progress and funding requirements for the remaining pipeline (NMRA-511, NMRA-898, NMRA-215) following the discontinuation of navacaprant.
- Legal Exposure: Monitor the status of the securities class action lawsuit and potential settlement costs or diversion of management resources.
- Contingent Liabilities: Review the specific triggers for the substantial milestone payments owed to BlackThorn, Vanderbilt, and Amgen, which could require significant cash or dilutive equity issuances.